Adjuvants are compounds that enhance the bodys immunogenic response against antigens. Hence, adjuvants are added to vaccines to increase their ability to induce long-term protection against infections. Vaccine adjuvants are in the process of development, and presently aluminum salts and MF59 are the only adjuvants found feasible for human use. R&D for potent vaccine adjuvants is progressing at a drastic rate after the development of new-generation vaccines. Modern-day vaccines are less immunogenic, thus resulting in the need for more powerful adjuvants for use in vaccines. This has to led to high investments by researchers and scientists to invest in R&D activities for safer and effective vaccine adjuvants, thus enhancing market growth.
Factors driving the world vaccine adjuvants market are rising support of government in R&D, high prevalence of diseases, increasing focus on improved vaccines, and strategic developmental moves adopted by companies such as agreements, acquisitions, and collaborations. However, side effects of adjuvants and cost of adjuvant development restrict the market growth. Moreover, emerging markets are opening avenues of opportunities for the growth of this market.
The market is segmented by product type, route of administration, disease type, application, and geography. On the basis of product type, it is divided into adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and others. In terms of route of administration, it is classified into oral, intramuscular, intranasal, subcutaneous, intradermal, and others. On the basis of disease type, it is segmented into cancer, infectious diseases, and others. Furthermore, on the basis of application it is bifurcated into research and commercial applications. Geographically, the market is analyzed across Europe, North America, Asia-Pacific, and LAMEA.
Major companies have conducted product launches, approvals, acquisitions, and collaborations for the development of novel vaccine adjuvants, thereby building a competitive landscape in the market. For instance, CSL Limited obtained approval for Seqirus flucelvax quadrivalent (Influenza Vaccine) from U.S. FDA, which provides protection against influenza virus A and B. Moreover, Agenus Inc. acquired PhosImmune Inc.; this acquisition helped Agenus in the development of new cancer vaccines as well as combination therapies.
Key players operating in this market are CSL Corporate, Brenntag Biosector A/S, Agenus, Inc., Novavax, Inc., Spectrum Pharmaceuticals, Inc., SEPPIC, Inc., Invivogen, Avanti Polar Lipids, Inc., MPV Technologies, and OZ Biosciences.
KEY MARKET BENEFITS:
- This report provides quantitative analysis of the current trends, future estimations, and dynamics through 20142022 in global vaccine adjuvants market, which assist in identifying the prevailing market opportunities.
- This study evaluates the competitive landscape and value chain to understand the competitive environment across the geographies.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- An in-depth analysis of the current research and clinical developments is provided, with key dynamic factors that facilitate in understanding the market behavior.
- Key market players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global vaccine adjuvants products.
KEY MARKET SEGMENTS:
By Product Type
- Adjuvant Emulsions
- Pathogen Components
- Particulate Adjuvants
- Combination Adjuvants
By Route of Administration
- Infectious Diseases
- By Application
- North America
- South Africa
- Middle East